Stay Tuned for Upcoming Coverage of the 2019 San Antonio Breast Cancer Symposium

Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.

Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.

Here are 4 sessions to watch for:

  • Frontiers in HER2 Positive Breast Cancer: Human epidermal growth factor receptor 2 (HER2) targeted therapies have significantly improved clinical outcomes in patients with HER2-positive breast cancer, and new therapies for patients with refractory diseases are being researched. By outlining the biology and mechanisms of resistance, researchers hope to be able to develop novel therapies. Keep an eye out for this session to get an overview of HER2 positive targeted therapies, both proven and in development.
  • Future of Immuno-Oncology in Breast Cancer: This mini-symposium aims to outline the role of immuno-oncology in breast cancer as it stands today, as well as how that role may change in the future. In addition to a discussion on enhancing patient response to immune checkpoint inhibitors, speakers will discuss the possibility of specifically targeting a common oncogene using T cell-based cancer immunotherapies, including genetically redirected T cells and therapeutic vaccines.
  • Targeting the Cell Cycle Kinase CDK 4/6 and Beyond: Along with several other sessions and video interviews discussing cyclin-dependent kinase (CDK) 4/6 inhibitors, this session will explain mechanisms of resistance, new therapeutic approaches, and specific treatments currently being researched. CDK 4/6 inhibitors have proven to have a major impact on patient outcomes and with plenty of developments in the pipeline, this will be a can’t-session.
  • General Session 1: In a study examining tucatinib versus a placebo, both combined with capecitabine and trastuzumab, researchers found that high levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. Keep an eye out for coverage of this session to get an understanding of this acquired resistance and how it can be treated.

In addition to these and other sessions, stay tuned for video coverage on topics such as clinical trials with patients, managing immunotherapy-related toxicities, the future of endocrine therapy, and more.